Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
NCT02431351 · Karyopharm Therapeutics Inc · PHASE2 · withdrawn · last registry update 2023-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial never opened.” | – | Registry record, Karyopharm Therapeutics Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XPO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-08Results posted on the registry: Karyopharm Therapeutics Inc, KCP-330 (NCT01896505)
- 2024-01-02Results posted on the registry: Children's Oncology Group, Selinexor (NCT02323880)
- 2023-12-06Phase 3 first posted: AbbVie, Etentamig + Carfilzomib (NCT06158841)
- 2023-11-07Results posted on the registry: Mohammed Najeeb Al Hallak, gemcitabine hydrochloride + Selinexor (NCT02178436)
- 2023-11-03Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-11-03Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-10-25Results posted on the registry: Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
- 2023-10-25Also stopped (terminated): Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
- 2023-06-15Results posted on the registry: Antengene Corporation, ATG-010 (NCT03944057)
- 2023-04-20Phase 3 first posted: The First Hospital of Jilin University, Selinexor (NCT05822050)
- 2023-02-16Results posted on the registry: Georgetown University, Open Label Selinexor (NCT03193437)
- 2023-02-16Also stopped (terminated): Georgetown University, Open Label Selinexor (NCT03193437)
- 2023-02-13Phase 3 first posted: Shanxi Bethune Hospital, Selinexor + Homoharringtonine (NCT05726110)
- 2023-01-26Also stopped (terminated): Karyopharm Therapeutics Inc, selinexor (NCT02138786)
- 2023-01-26Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor (NCT01986348)
- 2023-01-26Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor (NCT02146833)
- 2023-01-26Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor (NCT02314247)
- 2023-01-26Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor + Placebo (for selinexor) (NCT02628704)
- 2023-01-26Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor + Lenalidomide (NCT02389543)
- 2023-01-26Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor (KPT-330) (NCT02213133)
- 2023-01-20Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor (NCT02367690)
- 2023-01-20Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor (NCT04355676)
- 2023-01-09Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2022-11-17Also stopped (withdrawn): Weill Medical College of Cornell University, Selinexor + Dexamethasone (NCT04984330)
- 2022-11-10Phase 3 first posted: Karyopharm Therapeutics Inc, Selinexor + Matching Placebo for selinexor (NCT05611931)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision